2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1646

Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1083

Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus

B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

9:00AM-11:00AM: Abstract Number: 1104

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Chronic Tendinopathy

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1856

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

9:00AM-11:00AM: Abstract Number: 1079

Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease

B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

9:00AM-11:00AM: Abstract Number: 1407

Disease Activity Trackers to Support Treat to Target Strategies: A Needs Assessment Survey

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1944

Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1731

Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1522

Disease Burden in Rheumatoid Arthritis (RA) Patients Who Have Secondary Osteoarthritis (OA) Is Lower Than in OA but Higher Than in RA with No Secondary OA

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1521

Disease Characteristics and Change of Arthritis Activity According to Treatment in Hepatitis B Surface Antigen Positive Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1331

Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1730

Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1256

Disparities in Total Knee Replacement: Population Losses in Quality-Adjusted Life Years Due to Differential Offer, Acceptance, and Complication Rates in African Americans

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1747

Dissecting the Role of Single Complement Deficiencies in a Novel Model for Apoptotic Cell-Induced Lupus

Systemic Lupus Erythematosus – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 1628

Distinct Baseline Serum Molecular Profile and Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Asian-Pacific Patients with Active Rheumatoid Arthritis Despite DMARD or Anti-Tnfα Therapy Across Two Global Phase 3 Trials

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].